Should I buy or sell Biophytis stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biophytis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPTS shares. View BPTS analyst ratings or view top-rated stocks .

What is Biophytis' stock price target for 2024?

1 brokers have issued 12 month target prices for Biophytis' stock. Their BPTS share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 5,070.6% from the stock's current price. View analysts price targets for BPTS or view top-rated stocks among Wall Street analysts .

How have BPTS shares performed in 2024?

Biophytis' stock was trading at $0.6707 at the start of the year. Since then, BPTS shares have decreased by 56.7% and is now trading at $0.2901. View the best growth stocks for 2024 here .

Are investors shorting Biophytis?

Biophytis saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 102,300 shares, an increase of 138.5% from the March 15th total of 42,900 shares. Based on an average trading volume of 294,300 shares, the days-to-cover ratio is presently 0.3 days. View Biophytis' Short Interest .

When did Biophytis' stock split?

Biophytis's stock reverse split on the morning of Tuesday, April 23rd 2024. The 1-40 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Biophytis IPO?

Biophytis (BPTS) raised $20 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,200,000 shares at $15.00-$18.00 per share. H.C. Wainwright served as the underwriter for the IPO.

How do I buy shares of Biophytis?

Shares of BPTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BPTS

Biophytis (BPTS) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free BPTS Stock Alerts

$0.29

-0.04 (-12.12%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.28
▼
$0.30
50-Day Range: $0.28
▼
$0.60
52-Week Range: $0.27
▼
$4.22

Volume: 182,733 shs
Average Volume: 284,643 shs
Market Capitalization: $4.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.00

Stock Analysis Analyst Forecasts Chart Competitors Financials Headlines SEC Filings Short Interest Social Media

Get Biophytis alerts:

Biophytis MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 5,070.6% Upside
$15.00 Price Target
Short Interest: Healthy
0.73% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -1.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.05) to ($0.02) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.09 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Biophytis has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Biophytis has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.73% of the outstanding shares of Biophytis have been sold short.
Short Interest Ratio / Days to Cover
Biophytis has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biophytis has recently increased by 138.46%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Biophytis does not currently pay a dividend.
Dividend Growth
Biophytis does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BPTS.

0.6

News and Social Media Coverage

News Sentiment
Biophytis has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Biophytis this week, compared to 1 article on an average week.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biophytis insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.70% of the stock of Biophytis is held by insiders.
Percentage Held by Institutions
Only 0.05% of the stock of Biophytis is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Biophytis are expected to grow in the coming year, from ($0.05) to ($0.02) per share.

See Top Rated MarketRank™ Stocks Here

Ad Altimetry

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

About Biophytis Stock (NASDAQ:BPTS)

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.

BPTS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BPTS Stock News Headlines

April 19, 2024 | americanbankingnews.com

Biophytis (NASDAQ:BPTS) Shares to Reverse Split on Tuesday, April 23rd

April 9, 2024 | theglobeandmail.com

Biotech Catches Major Premarket Bid Following Financial Results

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

April 9, 2024 | finance.yahoo.com

Why Is Penny Stock Biophytis Trading Higher On Tuesday?

April 9, 2024 | investorplace.com

Why Is Biophytis (BPTS) Stock Up 43% Today?

April 8, 2024 | finanznachrichten.de

Biophytis announces its 2023 financial results -2-

April 4, 2024 | finance.yahoo.com

Results of the Combined General Meeting on April 2, 2024

March 22, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 19, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Flat in Tuesday Trading

March 12, 2024 | msn.com

European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading

December 20, 2023 | msn.com

European Equities Traded in the US as American Depositary Receipts Edge Higher Wednesday

October 30, 2023 | finance.yahoo.com

Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil

October 27, 2023 | marketwatch.com

Biophytis ADS Fall 8.5% in After Receiving Nasdaq Notice

October 27, 2023 | finance.yahoo.com

Biophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings Panel

September 29, 2023 | proactiveinvestors.com

Biophytis shares surge 41% following Covid partnership with France's Skyepharma

September 26, 2023 | finance.yahoo.com

Biophytis (BPTS) Soars 73% on Partnership With Skyepharma

September 25, 2023 | benzinga.com

Why Biophytis (BPTS) Shares Are Sky-Rocketing

September 25, 2023 | markets.businessinsider.com

Biophytis Shares Surge 79% Following Covid-19 Partnership With Skyepharma

September 25, 2023 | marketwatch.com

Biophytis Shares Rise 41% After Partnership Deal With Skyepharma

September 25, 2023 | finance.yahoo.com

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

September 25, 2023 | msn.com

Why Is Biophytis (BPTS) Stock Up 49% Today?

September 25, 2023 | finance.yahoo.com

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

September 20, 2023 | finanznachrichten.de

Biophytis Provides an Update on its Early Access Programs for Sarconeos in the Treatment of Severe Forms of COVID-19

September 19, 2023 | finance.yahoo.com

Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19

September 14, 2023 | finance.yahoo.com

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

September 11, 2023 | finanznachrichten.de

Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia

See More Headlines

Receive BPTS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biophytis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BPTS
CUSIP: N/A
CIK: 1768946
Web: www.biophytis.com
Phone: 33-1-44-37-23-00
Fax: N/A
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.00
High Stock Price Target: $15.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +5,072.4%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.72
Quick Ratio: 0.72

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.43) per share
Price / Book: -0.67

Miscellaneous

Outstanding Shares: 14,050,000
Free Float: 13,527,000
Market Cap: $4.07 million
Optionable: Not Optionable
Beta: 1.05

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Stanislas Veillet Ph.D. (Age 59)
Chairman of the Board & CEO
Comp: $463.6k
Mr. Nicolas Fellmann (Age 56)
Chief Financial Officer
Mr. Waly Dioh Ph.D. (Age 55)
Chief Clinical Operating Officer
Dr. Pierre J. Dilda (Age 54)
Chief Scientific Officer
Dr. Rene Lafont (Age 78)
Scientific Advisor & Member of Scientific Advisory Board
Dr. Rob van Maanen FFPM (Age 54)
M.B.A., M.D., Chief Medical Officer
Mr. Edouard Bieth
Chief Business Officer
Ms. _ Teylan
Financial Controller

Key Competitors

View All Competitors

BPTS Stock Analysis - Frequently Asked Questions

Should I buy or sell Biophytis stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biophytis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BPTS shares.
View BPTS analyst ratings or view top-rated stocks.
What is Biophytis' stock price target for 2024?: 1 brokers have issued 12 month target prices for Biophytis' stock. Their BPTS share price targets range from $15.00 to $15.00. On average, they anticipate the company's share price to reach $15.00 in the next twelve months. This suggests a possible upside of 5,070.6% from the stock's current price.
View analysts price targets for BPTS or view top-rated stocks among Wall Street analysts.
How have BPTS shares performed in 2024?: Biophytis' stock was trading at $0.6707 at the start of the year. Since then, BPTS shares have decreased by 56.7% and is now trading at $0.2901.
View the best growth stocks for 2024 here.
Are investors shorting Biophytis?: Biophytis saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 102,300 shares, an increase of 138.5% from the March 15th total of 42,900 shares. Based on an average trading volume of 294,300 shares, the days-to-cover ratio is presently 0.3 days.
View Biophytis' Short Interest.

When did Biophytis' stock split?: Biophytis's stock reverse split on the morning of Tuesday, April 23rd 2024. The 1-40 reverse split was announced on Tuesday, April 23rd 2024. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, April 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.
When did Biophytis IPO?: Biophytis (BPTS) raised $20 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,200,000 shares at $15.00-$18.00 per share. H.C. Wainwright served as the underwriter for the IPO.
How do I buy shares of Biophytis?: Shares of BPTS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BPTS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Biophytis (BPTS) Stock Price, News & Analysis

Biophytis MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Biophytis Stock (NASDAQ:BPTS)

BPTS Stock Price History

BPTS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

BPTS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™